A61P 11/12
Mucolytics
A61P11/12 (Mucolytics) appears on 331 US grants and 483 published applications in this corpus.
Search patents in A61P- Granted patents
- 331
- Published applications
- 483
- Assignees
- 223
- Inventors
- 882
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 2 | 0 |
| 1996 | 2 | 0 |
| 1997 | 4 | 0 |
| 1998 | 8 | 0 |
| 1999 | 3 | 0 |
| 2000 | 3 | 0 |
| 2001 | 5 | 5 |
| 2002 | 4 | 8 |
| 2003 | 9 | 13 |
| 2004 | 2 | 21 |
| 2005 | 7 | 15 |
| 2006 | 3 | 13 |
| 2007 | 13 | 17 |
| 2008 | 14 | 20 |
| 2009 | 10 | 19 |
| 2010 | 11 | 20 |
| 2011 | 17 | 29 |
| 2012 | 16 | 21 |
| 2013 | 24 | 21 |
| 2014 | 23 | 23 |
| 2015 | 15 | 25 |
| 2016 | 9 | 22 |
| 2017 | 18 | 24 |
| 2018 | 17 | 26 |
| 2019 | 16 | 22 |
| 2020 | 13 | 23 |
| 2021 | 20 | 21 |
| 2022 | 5 | 19 |
| 2023 | 11 | 21 |
| 2024 | 3 | 12 |
| 2025 | 14 | 15 |
| 2026 | 8 | 8 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Treatment of cystic fibrosis by delivery of codon-optimized mRNA encoding CFTR11 Aug 2026US 12,702,693 B2Translate Bio, Inc.
- Macrocyclic compounds, compositions, and methods of using thereof9 Jun 2026US 12,649,750 B2Genzyme Corporation
- Macrocyclic compounds, compositions, and methods of using thereof12 May 2026US 12,624,051 B2Genzyme Corporation
- Pyrrolopyrimidines as CFTR potentiators28 Apr 2026US 12,612,409 B2Cystic Fibrosis Foundation
- Dosage regime17 Mar 2026US 12,576,050 B2Novabiotics Limited
- Lung-Specific Targeting-Peptide (LTP), Compositions, and Uses Thereof27 Aug 2026US 2026/0250319 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
- Vitamin b2 for use in improving gut health16 Jul 2026US 2026/0199362 A1Dsm IP Assets B.V.
- RNAi Agents for Inhibiting Expression of Mucin 5AC (MUC5AC), Compositions Thereof, and Methods of Use21 May 2026US 2026/0139251 A1Arrowhead Pharmaceuticals, Inc.
- Synergistic Stimulation of Mucociliary Clearance to Treat Mucus Obstruction in Cystic Fibrosis and Other Muco-Obstructive Disorders26 Mar 2026US 2026/0083698 A1The Board of Trustees of the Leland Stanford Junior University
- Compositions and methods for treating and ameliorating respiratory conditions and inflammation of mucosa29 Jan 2026US 2026/0027140 A1Atopic Medical, LLC
Most cited
By later US patents
- Methods and compounds for the treatment of mucus hypersecretion169US 6,632,440 B1Health Protection Agency · 2003
- Indole derivatives as CFTR modulators130US 7,645,789 B2Vertex Pharmaceuticals Incorporated · 2010
- Modulators of ATP-binding cassette transporters121US 7,776,905 B2Vertex Pharmaceuticals Incorporated · 2010
- Method and device for the provocation of air passage narrowing and/or the induction of sputum116US 5,817,028 ACentral Sydney Area Health Service · 1998
- Method of treating lung disease with uridine triphosphates107US 5,292,498 AThe University of North Carolina at Chapel Hill · 1994